Phathom Pharmaceuticals Announces FDA Approval Of VOQUEZNA Tablets For Treatment Of Erosive GERD And Relief Of Heartburn Associated With Erosive GERD In Adults
Portfolio Pulse from Benzinga Newsdesk
Phathom Pharmaceuticals has received FDA approval for VOQUEZNA tablets, a treatment for erosive GERD and relief of heartburn in adults.
November 01, 2023 | 9:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phathom Pharmaceuticals' stock may see positive movement following the FDA approval of its VOQUEZNA tablets for the treatment of erosive GERD and heartburn relief in adults.
FDA approval of a new drug is a significant milestone for pharmaceutical companies. This approval could lead to increased sales and revenues for Phathom Pharmaceuticals, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100